Back to Resource Center

Investment in post-efficacy R&D critical for PrEP, other new HIV prevention options

Investment in post-efficacy R&D critical for PrEP, other new HIV prevention options

July 2015

Click to view Press Release

Click for full info +

Investment in post-efficacy R&D critical for PrEP, other new HIV prevention options

Investment in post-efficacy R&D critical for PrEP, other new HIV prevention options
17 July 2015
click to view Press Release
In this Press Release:
Health Risk(s):

  • HIV
    • Product Type(s):

  • Other or N/A
    • Topic(s):

  • Advocacy
  • Funding


    • Full Info:


    Resource Type:

    Press Release

    Citation:

    (2015, July 17). AVAC. 

    Authors:

    [no authors listed]

    Health Risks(s):

    • HIV

    Product type(s):

    • Microbicide
    • MPTs
    • Vaccines

    Topic(s):

    • Advocacy
    • Funding

        URL of resource:

        http://www.avac.org/press-release/investment-post-efficacy-rd-critical-prep-other-new-hiv-prevention-options

        Back to Resource Center